Public Citizen Letter for the Record of House Oversight Committee Hearing on HIV Prevention Medication

Public Citizen Letter for the Record on HIV Prevention Drug

On May 16, 2019,  the U.S. House Committee on Oversight and Reform held a hearing to investigate Gilead Sciences’ exorbitant price for the publicly funded breakthrough HIV prevention medication, Truvada. Public Citizen filed a letter for the record, with seven other organizations representing health care providers, public health experts, and consumer and taxpayer advocates. The signatories request the Committee to recommend reforms to ensure that all Americans who need pre-exposure prophylaxis (PrEP) are able to receive it, and that the public always receives a fair return on its research and development investment.